Non-Small Cell Lung Cancer (NSCLC)

Based on results of the VISION study, the FDA has granted accelerated approval to tepotinib for MET exon 14 skipping altered metastatic non–small cell lung cancer.

According to trial investigators, the results of the ongoing BFBC008 study point support the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory non–small cell lung cancer.

According to the study authors, an end-to-end deep learning approach to generate CT-based biomarkers may help produce more rapid clinical translation.

The MET inhibitor tepotinib demonstrated durable clinical activity in non‒small cell lung cancer tumors harboring MET exon 14 skipping mutations.

“Preliminary TRIDENT-1 data are very encouraging and support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC,” according to Byoung Chul Cho, MD, PhD.

Savolitinib plus osimertinib overcomes treatment resistance in non–small cell lung cancer with oncogenic driver mutations.

The phase 3 NeoADAURA trial will examine both single-agent osimertinib as well as the combination with platinum-based chemotherapy versus chemotherapy alone in the neoadjuvant setting in patients with resectable, stage II to IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.

Multiple key efficacy end points continue to favor atezolizumab versus chemotherapy for patients with PD-L1–high, wild-type nonsquamous or squamous non–small cell lung cancer in the first line, according to a phase 3 trial follow-up.

The investigational TROP-2–directed antibody-drug conjugate datopotamab deruxtecan will move forward in the treatment of relapsed/refractory non–small cell lung cancer, according to results from the 2020 World Conference on Lung Cancer Singapore.

Safety and antitumor activity of mobocertinib became evident after results of a trial involving EGFR exon 20 insertion–mutant non–small cell lung cancer were reported at the 2020 World Conference on Lung Cancer Singapore.

Results from the phase 2/3 KEYNOTE-010 trial continue to favor pembrolizumab, including key survival end points.

Patients with KRAS G12C–mutated advanced non–small cell lung cancer show antitumor response and survival benefit with the KRAS G12C inhibitor sotorasib, formerly AMG 510.

Results from the phase 3 ADAURA trial found extended disease-free survival for patients, irrespective of previous adjuvant chemotherapy received or disease stage.

A Japanese study supports the use of nab-paclitaxel for previously treated non–small cell lung cancer based on noninferiority end points being met.

Trastuzumab deruxtecan treatment demonstrated strong antitumor activity for patients with HER2-overexpressing NSCLC, regardless of HER2 expression levels, according to interim findings from the phase 2 DESTINY Lung-01 trial.

Results of the phase 1 CHRYSALIS trial demonstrated the safety and efficacy of amivantamab in patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

This ongoing study supports the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory non—small cell lung cancer, according to Matthew G. Krebs, MB ChB, FRCP, PhD.

Follow up data from KEYNOTE-799 demonstrated a high overall response rate with no new safety signals for patients with unresectable, locally advanced, stage III non-small cell lung cancer.

A real-world study enlightens to the importance of NRG1 fusions in non–small cell lung cancer and provides possible steps forward.

Results from the 2020 World Conference on Lung Cancer Singapore demonstrated the feasibility of using STK11 mutations and immune-related adverse events as response predictors in patients with non–small cell lung cancer.

An updated analysis presented at the 2020 World Conference on Lung Cancer Singapore expanded on data investigating pembrolizumab in the treatment of patients with PD-L1–positive NSCLC without sensitizing EGFR/ALK alterations.

Supporting previously reported data, updated results of the phase 3 KEYNOTE-189 trial indicate that overall survival is significantly improved when pembrolizumab is added to platinum-based chemotherapy in the frontline treatment of patients with metastatic nonsqamous NSCLC.

Though previous reports have suggested that an EGFR tyrosine kinase inhibitor plus an anti-VEGF agent might offer benefit to patients with brain metastasis or pleural effusion, the study authors could not identify its advantage.

The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.